Technical Analysis for DCTH - Delcath Systems, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 4.18 | 5.29% | 0.21 |
DCTH closed up 5.29 percent on Monday, March 18, 2024, on 71 percent of normal volume. It ran into resistance at its 50 day moving average. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.
Earnings due: Mar 25
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
200 DMA Resistance | Bearish | 0.00% | |
50 DMA Resistance | Bearish | 0.00% | |
Crossed Above 20 DMA | Bullish | 0.00% | |
Bollinger Band Squeeze | Range Contraction | 0.00% | |
20 DMA Resistance | Bearish | 5.29% | |
50 DMA Resistance | Bearish | 5.29% | |
Shooting Star Candlestick | Bearish | 5.29% | |
Slingshot Bearish | Bearish Swing Setup | 5.29% | |
Stochastic Buy Signal | Bullish | 5.29% | |
Pocket Pivot | Bullish Swing Setup | 5.29% |
Alert | Time |
---|---|
Down 1% | about 11 hours ago |
50 DMA Resistance | about 13 hours ago |
Rose Above Previous Day's High | about 14 hours ago |
Rose Above 50 DMA | about 14 hours ago |
Up 5% | about 14 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/25/2024
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's investigational products include melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. Its clinical development program consists of FOCUS Trial for the patients with hepatic dominant ocular melanoma; and ALIGN Trial that is in Phase 3 clinical trial for intrahepatic cholangiocarcinoma. It also offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.
Sector: Healthcare
Industry: Medical Devices
Keywords: Medicine Clinical Development Oncology Chemotherapy Melanoma Chloride Specialty Drugs Carcinoma Hepatology Liver Cancer Cholangiocarcinoma Interventional Oncology Intrahepatic Cholangiocarcinoma Ocular Melanoma
Classification
Sector: Healthcare
Industry: Medical Devices
Keywords: Medicine Clinical Development Oncology Chemotherapy Melanoma Chloride Specialty Drugs Carcinoma Hepatology Liver Cancer Cholangiocarcinoma Interventional Oncology Intrahepatic Cholangiocarcinoma Ocular Melanoma
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 7.99 |
52 Week Low | 2.25 |
Average Volume | 203,859 |
200-Day Moving Average | 4.31 |
50-Day Moving Average | 4.28 |
20-Day Moving Average | 4.07 |
10-Day Moving Average | 3.92 |
Average True Range | 0.22 |
RSI (14) | 52.61 |
ADX | 17.92 |
+DI | 25.07 |
-DI | 17.16 |
Chandelier Exit (Long, 3 ATRs) | 4.14 |
Chandelier Exit (Short, 3 ATRs) | 4.37 |
Upper Bollinger Bands | 4.41 |
Lower Bollinger Band | 3.73 |
Percent B (%b) | 0.66 |
BandWidth | 16.79 |
MACD Line | -0.11 |
MACD Signal Line | -0.10 |
MACD Histogram | -0.0026 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 4.78 | ||||
Resistance 3 (R3) | 4.76 | 4.55 | 4.68 | ||
Resistance 2 (R2) | 4.55 | 4.39 | 4.56 | 4.65 | |
Resistance 1 (R1) | 4.36 | 4.30 | 4.46 | 4.38 | 4.61 |
Pivot Point | 4.15 | 4.15 | 4.19 | 4.16 | 4.15 |
Support 1 (S1) | 3.96 | 3.99 | 4.06 | 3.98 | 3.75 |
Support 2 (S2) | 3.75 | 3.90 | 3.76 | 3.71 | |
Support 3 (S3) | 3.56 | 3.75 | 3.68 | ||
Support 4 (S4) | 3.58 |